Efficacy and Safety of Gecacitinib Hydrochloride in Prophylaxis Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelofibrosis (Gecacitinib)
Efficacy and Safety of Gecacitinib Hydrochloride Combined With Rabbit Anti-Human Thymocyte Immunoglobulin (ATG) in Prophylaxis Acute Graft-Versus-Host Disease (aGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) in Patients With Myelofibrosis (MF)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Na Xu Nanfang Hospital, Southern Medical University
- Phone Number: 020-62787238
- Email: nfyyec@163.com
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Voluntarily sign the informed consent form (ICF), and be aged ≥ 18 years at the time of signing.
- Diagnosis of primary myelofibrosis (PMF) according to the 2016 WHO criteria (DIPSS intermediate-2/high risk, MPISS70 high/very high risk, or RR6 high risk), or post-ET/PV secondary myelofibrosis (MYSEC intermediate-2/high risk), with intention to undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT).
- Recipient with myelofibrosis scheduled to receive myeloablative conditioning allo-HSCT from a matched unrelated donor, matched sibling donor, or haploidentical donor.
- Karnofsky Performance Scale score ≥ 60.
- Eastern Cooperative Oncology Group (ECOG) performance status score 0-2.
- Male participants must agree to abstinence or use barrier contraception throughout the study.
- Female participants of childbearing potential must have a negative pregnancy test and agree to use two effective methods of contraception throughout the study.
- Ability to swallow tablets.
- Ability to comply with study and follow-up procedures.
Exclusion Criteria:
- Prior treatment with chimeric antigen receptor T-cell (CAR-T) therapy.
- Hepatic insufficiency defined as bilirubin ≥ 2 × upper limit of normal (ULN), except for patients with a history of Gilbert Syndrome.
- Renal impairment defined as serum creatinine > 2 mg/dL.
- Cardiac dysfunction defined as left ventricular ejection fraction (LVEF) ≤ 45%.
- Pulmonary dysfunction defined as forced expiratory volume in the first second (FEV1) or diffusing capacity for carbon monoxide (DLCO) (corrected for hemoglobin) ≤ 50% of predicted value.
- Chronic or active infection requiring systemic therapy during the peri-transplant and post-transplant period.
- Diagnosis of another active malignancy within the past 12 months, except for adequately treated non-melanoma skin cancer, adequately treated melanoma of grade 2 or below, or cervical intraepithelial neoplasia. Active malignancy is defined as malignancy undergoing active treatment.
Any significant clinical or laboratory abnormality that may compromise safety evaluation, such as:
- Uncontrolled diabetes mellitus (fasting blood glucose > 13.9 mmol/L);
- Hypertension uncontrolled by two or more antihypertensive agents (systolic blood pressure ≥ 160 mmHg, diastolic blood pressure ≥ 100 mmHg);
- Peripheral neuropathy of grade ≥ 2 per NCI-CTCAE v5.0.
- Pre-transplant diagnosis of gastrointestinal impairment or disease that may affect drug absorption, including ulcerative disease, uncontrolled nausea, vomiting, diarrhea, or history of gastrectomy or intestinal resection.
- Cholestatic disease or sinusoidal obstruction syndrome / hepatic veno-occlusive disease at screening (defined as persistent bilirubin abnormality and progressive organ dysfunction not due to graft-versus-host disease).
- Active and uncontrolled viral infection at screening, including CMV, EBV, HIV (positive anti-HIV antibody), HBV (positive HBsAg or positive HBV-DNA), HCV (positive anti-HCV antibody or positive HCV-RNA).
- Active tuberculosis within 6 months prior to screening.
- History of epilepsy or use of psychotropic or sedative medications at screening.
- Female patients who are pregnant, breastfeeding, or planning pregnancy, or who cannot use effective contraception throughout the study; male patients who do not use condoms during dosing and for 2 days (approximately 5 half-lives) after the last dose.
- History of malignancy other than the transplanted tumor within the previous 5 years.
- Use of anticoagulant or antiplatelet agents (except low-molecular-weight heparin).
- Presence of other severe diseases that, in the investigator's opinion, may affect patient safety or compliance.
- Suspected hypersensitivity to geltrectinib hydrochloride, its analogs, or any of its excipients.
- Participation in another clinical trial of an investigational drug or medical device within 4 weeks prior to screening.
- Any other condition that, in the investigator's judgment, renders the patient ineligible for the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Gecacitinib Hydrochloride in Combination with Rabbit Anti-human Thymocyte Immunoglobulin (ATG)
|
(i) Rabbit anti-human thymocyte immunoglobulin (ATG): administered on Days -4 to -2.(ii) Cyclosporine A: initiated on Day -9 through Day +180, tapered gradually after Day +90.(iii)
Mycophenolate mofetil (MMF): administered at 0.5 g twice daily (bid) from Day -9 to Day +30.(iv)
Geltrectinib hydrochloride: administered between Day +6 and Day +28 post-engraftment at a dose of 50 mg twice daily (bid).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of grade 3-4 aGVHD
Time Frame: 14 weeks.
|
Proportion of patients with grade 3-4 acute graft-versus-host disease (aGVHD) within 14 weeks.
|
14 weeks.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of poor graft function
Time Frame: 14 weeks
|
In the setting of complete donor chimerism, mild or moderate cytopenia exists in at least two hematopoietic cell lineages (ANC ≤ 1.5×10⁹/L; platelet count ≤ 30×10⁹/L, Hb ≤ 85 g/L) and persists for more than 2 weeks.
|
14 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- Saad, Ayman, Marcos de Lima, Sarah Anand, Vijaya Raj Bhatt, Ryan Bookout, George Chen, Daniel Couriel et al. "Hematopoietic Cell Transplantation, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology." Journal of the National Comprehensive Cancer Network 18, no. 5 (2020): 599-634.
- Zhang Y, Zhou H, Zhuang J, et al. A randomized, double-blind, phase 3 study of jaktinib versus hydroxyurea (HU) in patients (pts) with intermediate-2 or high-risk myelofibrosis (MF). Journal of Clinical Oncology 41, no. 16_suppl (2023): 7015-7015.
- De Togni E, Cole O, Abboud R. Janus kinase inhibition in the treatment and prevention of graft-versus-host disease. Front Immunol. 2024 Feb 6;15:1304065.
Helpful Links
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- NFEC-2026-043
- GCA-aGVHD-002 (Other Grant/Funding Number: Suzhou Zejing Biopharmaceutical Co., Ltd.)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.